


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended) A compound having the formula (I):




(I)

or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:

*A* is  $\text{C}_{1-6}$  alkylene; *R*, *R*<sub>1</sub> and *R*<sub>2</sub> are independently hydrogen, halo, haloalkyl, aryl, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, hydroxyalkyl, nitro, amino, cyano, cyanamido, guanidine, amidino, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido, S-alkyl or alkylthiol alkylthiol; *X* is  $>\text{C}_{1-6}$  alkylene,  $>\text{C=O}$  or  $>\text{C=S}$  or a single bond; and *Y* is hydrogen, halo, haloalkyl, aryl, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, hydroxyalkyl, nitro, amino, cyano, cyanamido, guanidine, amidino, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy,

carbonylamido, or styryl, wherein where Y is a ring it which may be ring-substituted by up to four substituents independently selected from among hydrogen, halo, haloalkyl, aryl, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, hydroxyalkyl, nitro, amino, cyano, cyanamido, guanidine, amidino, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, S-alkyl, alkylthiol alkylthiol or -COQ, where Q is hydroxy, C<sub>1-6</sub> alkoxy, amino, mono- C<sub>1-6</sub> alkylamino, di- C<sub>1-6</sub> alkylamino, hydroxylamino, C<sub>1-4</sub> alkoxyamino or aryl-C<sub>1-4</sub>-alkoxyamino; but excluding (a) the compounds where simultaneously X is >C=O, Y is methyl, A is CH<sub>2</sub>CH<sub>2</sub>, R is 5-methoxy, R<sub>1</sub> is H or formyl and R<sub>2</sub> is H, (b) the compounds where the moiety -A(R<sub>2</sub>)-NH-X-Y is -CH<sub>2</sub>CH(COQ)-NH<sub>2</sub> or -CH(haloalkyl)-CH(COQ)-NH<sub>2</sub>, and (c) the compounds where simultaneously X is a single bond, Y is arylalkyl, A is CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, both R<sub>1</sub> and R<sub>2</sub> are H and R is 4-halo where the moiety -CO-A(R<sub>2</sub>)-NH-X-Y is deemed to be in the 1-position of the depicted benzene ring.

2. (Currently amended) A compound according to claim 1, having formula (II):



(II)

wherein R is hydrogen, methyl or methoxy, R<sub>1</sub> is hydrogen or formyl, R<sub>2</sub> is hydrogen or carboxyl, and R<sub>3</sub> is hydrogen, halo, haloalkyl, aryl, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, hydroxyalkyl, nitro, amino, cyano, cyanamido, guanidine, amidino, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido, S-alkyl or alkylthiol, alkylthiol; and stereoisomers and pharmaceutically acceptable salts thereof.

3. (Currently amended) Compounds according to claim 1, where in formula (I), Y is 2-furyl, 2-dihydrofuryl, or 2-tetrahydrofuryl or  $(2-R^{\circ}-COO-)phenyl$ , any of which may be substituted by 1-2 substituents selected from C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, OH, nitro, or Y is hydrogen or styryl which is ring-substituted by up to two substituents independently selected from among halogen, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, OH, nitro, aryl, aryl-C<sub>1-4</sub> alkyl, or aryl-C<sub>1-4</sub> alkoxy, and stereoisomers and pharmaceutically acceptable salts thereof.

4. (Previously presented) Compounds according to claim 1, and stereoisomers and pharmaceutically acceptable salts thereof, where in formula (I), R<sub>2</sub> is hydrogen and at least one of the following conditions applies, namely:

R is 5-methoxy; or

A is CH<sub>2</sub>CH<sub>2</sub> or CH<sub>2</sub>CHCOOH; or

R<sub>1</sub> is hydrogen; or

X is a single bond and Y is a 2,4-dinitrophenyl group.

5. (Original) Compounds according to claim 1, and stereoisomers and pharmaceutically acceptable salts thereof, where in formula (I), X and Y are selected in combination as follows:

X is -CO- and Y is 2-furyl; or

X is -CO- and Y is 2-tetrahydrofuryl; or

X is -CH<sub>2</sub>- and Y is 2-tetrahydrofuryl; or

X is -CO- and Y is 2-acetoxyphenyl; or

X is -CO- and Y is 3,4-dihydroxystyryl or 3,4-dihydroxycinnamoyloxy.

6. (Previously presented) Compounds according to claim 5, wherein at least one of the following conditions applies, namely:

R is 5-methoxy; or

A is  $\text{CH}_2\text{CH}_2$  or  $\text{CH}_2\text{CHCOOH}$ ; or

$R_1$  is hydrogen.

7. (Original) A compound according to claim 1, which is 3-(2-aminobenzoyl)-2-(2,4-dinitroanilino)propanoic acid, and stereoisomers and pharmaceutically acceptable salts thereof.

8. (Previously presented) A compound according to claim 1, which is 2-(2-aminobenzoyl)-N-(2,4-dinitrophenyl)ethylamine, or a pharmaceutically acceptable salt thereof.

9. (Original) A pharmaceutical formulation containing a therapeutically effective amount of at least one compound as defined in claim 1, in association with at least one pharmaceutically acceptable ingredient selected from diluents, preservatives, solubilizers, emulsifiers, adjuvants, excipients and carriers.

10. (Original) A pharmaceutical formulation according to claim 9, which is further characterized by at least one of the following features:

- (i) it is adapted for oral, rectal, parenteral, transbuccal, intrapulmonary or transdermal administration;
- (ii) it is in unit dosage form, each unit dosage comprising an amount of said at least one compound which lies within the range of 0.0025-1000 mg;
- (iii) it is a controlled release formulation, wherein said at least one compound is released at a predetermined controlled rate;
- (iv) it comprises additionally at least one known therapeutically active ingredient selected from neuroleptics, thymoleptics, anxiolitics, tranquilizers, analgesics, and antiparkinson's drugs.

11. (Currently amended) A method of treating a subject suffering from a physiological condition selected from the group consisting of stroke, ischemia, CNS trauma, hypoglycemia and surgery, CNS disorders ~~including neurodegenerative diseases~~, overstimulation of the excitatory amino acids, psychiatric disorders, epilepsy and or other convulsive disorders, anxiety, psychosis, senile dementia, multi-infarct dementia, chronic pain (analgesia), glaucoma, CMV retinitis, urinary incontinence, ~~and for inducing anesthesia, enhancing cognition, and preventing opiate tolerance and withdrawal symptoms, impotence, cardiovascular disorders including hypertension, preventing blood coagulation, neuropathy, anti-inflammatory, chronobiological-related~~


disorders, seasonal-related disorders, endocrine indications, ~~contraception and infertility~~, precocious puberty, premenstrual syndrome, hyperprolactinemia, ~~and~~ growth hormone deficiency, neoplastic disease, ~~other proliferative diseases (benign or and tumor prostate growth)~~, immune system disorders, conditions associated with senescence, ophthalmological diseases, cluster headache, migraine, ~~skin protection; diabetes stabilization or and~~ weight gain disorders, which comprises administering a therapeutically effective amount of a compound of formula I or a stereoisomer or a pharmaceutically acceptable salt thereof as defined in claim 1.

12. (Previously presented) The method of claim 11, wherein said compound or stereoisomer or salt is administered in a pharmaceutical formulation as defined in claim 9.

13. (Previously presented) The method of claim 12, wherein said pharmaceutical formulation is as defined in claim 10.

14. (Previously presented) A method for regulating fertility, puberty or pelage color in animal breeding, which comprises administering to a breeding animal an effective amount of a compound of formula I or a stereoisomer or pharmaceutically acceptable salt as defined in claim 1.

15. (New) A compound having the formula (I):




(I)

or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:

A is C<sub>1-6</sub> alkylene; R, R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, halo, haloalkyl, aryl, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, hydroxyalkyl, nitro, amino, cyano, cyanamido, guanidine, amidino, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido, S-alkyl or alkylthiol, X is >C<sub>1-6</sub> alkylene, >C=O or >C=S; and Y is hydrogen, halo, haloalkyl, aryl, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, hydroxyalkyl, nitro, amino, cyano, cyanamido, guanidine, amidino, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido, or styryl, wherein where Y is a ring it may be ring-substituted by up to four substituents

independently selected from among hydrogen, halo, haloalkyl, aryl, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, hydroxyalkyl, nitro, amino, cyano, cyanamido, guanidine, amidino, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, S-alkyl, alkylthiol or -COQ, where Q is hydroxy, C<sub>1-6</sub> alkoxy, amino, mono- C<sub>1-6</sub> alkylamino, di- C<sub>1-6</sub> alkylamino, hydroxylamino, C<sub>1-4</sub> alkoxyamino or aryl-C<sub>1-4</sub>-alkoxyamino; but excluding (a) the compounds where simultaneously X is >C=O, Y is methyl, A is CH<sub>2</sub>CH<sub>2</sub>, R is 5-methoxy, R<sub>1</sub> is H or formyl and R<sub>2</sub> is H and (b) the compounds where the moiety -A(R<sub>2</sub>)-NH-X-Y is -CH<sub>2</sub>CH(COQ)-NH<sub>2</sub> or -CH(haloalkyl)-CH(COQ)-NH<sub>2</sub>.

16. (New) A compound having the formula (I):



(I)

or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:

A is  $\text{C}_{1-6}$  alkylene; R,  $\text{R}_1$  and  $\text{R}_2$  are independently halo, haloalkyl, aryl, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, hydroxyalkyl, nitro, amino, cyano, cyanamido, guanidine, amidino, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido, S-alkyl or alkylthiol, and each of  $\text{R}_1$  and  $\text{R}_2$  independently also can be hydrogen, X is  $>\text{C}_{1-6}$  alkylene,  $>\text{C}=\text{O}$ ,  $>\text{C}=\text{S}$  or a single bond; and Y is hydrogen, halo, haloalkyl, aryl, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, hydroxyalkyl, nitro, amino, cyano, cyanamido, guanidine, amidino, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido, or styryl, wherein where Y is a ring it may be ring-

substituted by up to four substituents independently selected from among hydrogen, halo, haloalkyl, aryl, a heterocyclic group, a heteroaryl group, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, hydroxyalkyl, nitro, amino, cyano, cyanamido, guanidine, amidino, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, S-alkyl, alkylthiol or -COQ, where Q is hydroxy, C<sub>1-6</sub> alkoxy, amino, mono- C<sub>1-6</sub> alkylamino, di- C<sub>1-6</sub> alkylamino, hydroxylamino, C<sub>1-4</sub> alkoxyamino or aryl-C<sub>1-4</sub>-alkoxyamino; but excluding (a) the compounds where simultaneously X is >C=O, Y is methyl, A is CH<sub>2</sub>CH<sub>2</sub>, R is 5-methoxy, R<sub>1</sub> is H or formyl and R<sub>2</sub> is H, (b) the compounds where the moiety -A(R<sub>2</sub>)-NH-X-Y is -CH<sub>2</sub>CH(COQ)-NH<sub>2</sub> or -CH(haloalkyl)-CH(COQ)-NH<sub>2</sub>, and (c) the compounds where simultaneously X is a single bond, Y is arylalkyl, A is CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, both R<sub>1</sub> and R<sub>2</sub> are H and R is 4-halo where the moiety -CO-A(R<sub>2</sub>)-NH-X-Y is deemed to be in the 1-position of the depicted benzene ring.

17. (New) A compound according to claim 15 or 16, where in formula (I), Y is 2-furyl, 2-dihydrofuryl or 2-tetrahydrofuryl, any of which may be substituted by 1-2 substituents selected from C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, OH, nitro, or Y is hydrogen or styryl which is ring-substituted by up to two substituents independently selected from among halogen, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, OH, nitro, aryl, aryl-C<sub>1-4</sub> alkyl, or aryl-C<sub>1-4</sub> alkoxy, and stereoisomers and pharmaceutically acceptable salts thereof.